![Chao Hong Hu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chao Hong Hu
Direktor/Vorstandsmitglied bei
HUTCHMED (CHINA) LIMITED
Vermögen: 68 Mio $ am 31.08.2026
Profil
Chao Hong Hu was the founder of Shanghai Miracogen, Inc., founded in 2014, serving as Chairman & General Manager from 2014 to 2024.
Current jobs include Independent Non-Executive Director at BioDlink International Co., Ltd. since 2026 and Independent Non-Executive Director at HUTCHMED (China) Ltd. since 2024.
Former jobs include Co-Chief Executive Officer & Executive Director at Lepu Biopharma Co., Ltd. from 2020 to 2024, Director-Molecular Biology & Clinical Immunology at ID Biomedical Corp., Director-Bioassay Development & Process Analytics at Seagen, Inc. from 2007 to 2013, and Head-Molecular Biology & Clinical Immunology at GSK Plc from 2006 to 2007.
Education includes an undergraduate degree from Wuhan University in 1986 and a doctorate from the Chinese Academy of Sciences.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.07.2025 | 121.180.106 ( 6,72 % ) | 68 Mio $ | 31.08.2026 |
Aktive Positionen von Chao Hong Hu
| Unternehmen | Position | Beginn |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Direktor/Vorstandsmitglied | 21.11.2024 |
| BIODLINK INTERNATIONAL COMPANY LIMITED | Direktor/Vorstandsmitglied | 29.04.2026 |
Ehemalige bekannte Positionen von Chao Hong Hu
| Unternehmen | Position | Ende |
|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Vorstandsvorsitzender | 31.01.2024 |
Shanghai Miracogen, Inc.
 Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Vorstandsvorsitzender | 01.01.2024 |
| SEAGEN INC. | Corporate Officer/Principal | 01.10.2013 |
| GSK PLC | Corporate Officer/Principal | 01.05.2007 |
ID Biomedical Corp.
 ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Corporate Officer/Principal | 01.01.2005 |
Ausbildung von Chao Hong Hu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
74
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
HUTCHMED (China) Ltd.
 HUTCHMED (China) Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Wuhan University
 Wuhan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chinese Academy of Sciences
 Chinese Academy of Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TOT BIOPHARM International Co. Ltd.
 TOT BIOPHARM International Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets anti-tumor drugs | Health Technology |
Lepu Biopharma Co., Ltd.
 Lepu Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Health Technology |
